In our series, HLH occurred following treatment with both PD-1 (pembrolizumab) and PD-L1 (atezolizumab) inhibitors, suggesting that the risk may not be restricted to a specific agent but rather reflect a class-wide immune activation mechanism. The gene discussed is CD274; the disease is hemophagocytic syndrome.